NCT01367236 - Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions

HIVImpaired Cognition

Interventions

DRUG

standard care

"* atazanavir 300 mg daily~* ritonavir 100 mg daily~* tenofovir 245 mg daily\*~* emtricitabine 200 mg daily\*"

DRUG

novel treatment

"* darunavir 800 mg daily~* ritonavir 100 mg daily~* lamivudine 300 mg daily\*\* and abacavir 600mgs daily\*\*~* maraviroc 150 mg once daily"

Trial Locations (6)

Birmingham Heartlands Hospital:, Birmingham

St. Thomas' Hospital, London

Brighton and Sussex University Hospital NHS Trust:, Brighton

Kings College Hospital, London

Chelsea and Westminster Hospital NHS Trust, London

St. Mary's Hospital, London